Form 4: ACHV COO Granted 180,000 Stock Options

Achieve Life Sciences' Chief Operations Officer, Craig Donnelly, was granted 180,000 stock options with an exercise price of $4.36.

Summary

• Craig Donnelly, Chief Operations Officer of ACHIEVE LIFE SCIENCES, INC. (ACHV), was granted 180,000 stock options.
• The options have an exercise price of $4.36 per share.
• The transaction date for the option grant was January 28, 2025.
• The options will vest as to 1/4 of the total award on the first anniversary of January 28, 2026, and thereafter in substantially equal monthly installments over 36 months.
• The vesting is subject to Mr. Donnelly's continued provision of service to the Issuer on each vesting date.
• The expiration date for these stock options is January 28, 2036.
• Following this transaction, Mr. Donnelly beneficially owns 180,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive, routine event. While it represents potential future dilution, it primarily serves to align management incentives with shareholder interests, which is generally favorable.

Positives

• The grant of stock options aligns the Chief Operations Officer's incentives with long-term shareholder value.
• Equity compensation is a standard practice for attracting and retaining key executive talent.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Future Outlook

The vesting schedule of the stock options over four years indicates an expectation of continued service from the Chief Operations Officer, aligning his long-term commitment with the company's performance.

Industry Context

StockSavvy.ai notes that equity compensation, such as stock option grants, is a prevalent and essential component of executive remuneration packages within the biotechnology and pharmaceutical sectors. This practice is designed to attract, retain, and motivate senior leadership by directly linking their financial success to the company's stock performance and long-term strategic goals.

Comparison to Industry Standards

• StockSavvy.ai notes that an option grant of 180,000 shares for a Chief Operations Officer is within the typical range for a clinical-stage biotechnology company like Achieve Life Sciences, comparable to similar grants observed at peers such as Xencor, Inc. (XNCR) or Mirati Therapeutics, Inc. (MRTX) for executives at similar levels, reflecting standard industry practices for incentivizing key personnel.

Related Party Transactions

• The grant of 180,000 stock options to Craig Donnelly, the Chief Operations Officer, constitutes a related party transaction as it involves an executive officer of the company.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from increased incentive alignment of a key executive.
• Chief Operations Officer (Craig Donnelly): Receives significant equity compensation, aligning personal financial interests with company performance.

Next Steps

• The stock options will begin vesting on January 28, 2026, with subsequent monthly installments over 36 months.

Key Dates

Keywords

ACHIEVE LIFE SCIENCES, ACHV, Stock Option, Insider Transaction, Craig Donnelly, Chief Operations Officer, Equity Compensation, Form 4